# Post Marketing Surveillance of Nintedanib in Indian Patients With Idiopathic Pulmonary Fibrosis

> **NCT03047031** · — · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 21 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis

## Interventions

- **DRUG:** Nintedanib
- **DRUG:** Pirfenidone

## Key facts

- **NCT ID:** NCT03047031
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-05
- **Primary completion:** 2022-07-21
- **Final completion:** 2022-07-21
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2025-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03047031

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03047031, "Post Marketing Surveillance of Nintedanib in Indian Patients With Idiopathic Pulmonary Fibrosis". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03047031. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*